Mumbai, April 17 -- The board of Windlas Biotech at its meeting held on 17 April 2026 has approved buyback of up to 4,70,000 fully paid up equity shares of the company (representing 2.23% of the paid up equity share capital) at a price of Rs 1,000 per equity share for an aggregate amount not exceeding Rs 47 crore.

Published by HT Digital Content Services with permission from Capital Market....